Fiocruz will be producing 11 million molecular tests for COVID-19

11 May 2020

Brazil’s Oswaldo Cruz Foundation (Fiocruz) will be producing 11 million molecular tests for COVID-19 for the country’s Ministry of Health (MS) by September. The Foundation began supplying the tests on March 4.

The goal of the first agreement was to produce 25,000 tests for Sars-CoV-2, to be used in the National Influenza Centers (Oswaldo Cruz Institute - IOC/Fiocruz, Adolfo Lutz Institute and Evandro Chagas Institute).

Also in March, as the number of cases associated to the COVID-19 pandemic increased in Brazil and worldwide, the need came to increase production. By March 28, about 60,000 tests had been delivered.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK